Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

35 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Practical implementation, education and interpretation guidelines for continuous glucose monitoring: A French position statement.
Borot S, Benhamou PY, Atlan C, Bismuth E, Bonnemaison E, Catargi B, Charpentier G, Farret A, Filhol N, Franc S, Gouet D, Guerci B, Guilhem I, Guillot C, Jeandidier N, Joubert M, Melki V, Merlen E, Penfornis A, Picard S, Renard E, Reznik Y, Riveline JP, Rudoni S, Schaepelynck P, Sola-Gazagnes A, Tubiana-Rufi N, Verier-Mine O, Hanaire H; Société francophone du diabète (SFD), Société française d’endocrinologie (SFE); Évaluation dans le diabète des implants actifs Group (EVADIAC). Borot S, et al. Among authors: melki v. Diabetes Metab. 2018 Feb;44(1):61-72. doi: 10.1016/j.diabet.2017.10.009. Epub 2017 Nov 11. Diabetes Metab. 2018. PMID: 29174479
Clinical evaluation of a newly designed compliant side port catheter for an insulin implantable pump: the EVADIAC experience. Evaluation dans le Diabete du Traitement par Implants Actifs.
Gin H, Melki V, Guerci B, Catargi B; Evaluation dans le Diabete du Traitement par Implants Actifs Study Group. Gin H, et al. Among authors: melki v. Diabetes Care. 2001 Jan;24(1):175. doi: 10.2337/diacare.24.1.175. Diabetes Care. 2001. PMID: 11194228 No abstract available.
Combined improvements in implantable pump technology and insulin stability allow safe and effective long term intraperitoneal insulin delivery in type 1 diabetic patients: the EVADIAC experience.
Gin H, Renard E, Melki V, Boivin S, Schaepelynck-Bélicar P, Guerci B, Selam JL, Brun JM, Riveline JP, Estour B, Catargi B; EVADIAC Study Group. Gin H, et al. Among authors: melki v. Diabetes Metab. 2003 Dec;29(6):602-7. doi: 10.1016/s1262-3636(07)70075-7. Diabetes Metab. 2003. PMID: 14707889 Clinical Trial.
Advantages to using capillary blood beta-hydroxybutyrate determination for the detection and treatment of diabetic ketosis.
Guerci B, Tubiana-Rufi N, Bauduceau B, Bresson R, Cuperlier A, Delcroix C, Durain D, Fermon C, Le Floch JP, Le Devehat C, Melki V, Monnier L, Mosnier-Pudar H, Taboulet P, Hanaire-Broutin H. Guerci B, et al. Among authors: melki v. Diabetes Metab. 2005 Sep;31(4 Pt 1):401-6. doi: 10.1016/s1262-3636(07)70211-2. Diabetes Metab. 2005. PMID: 16369204 Review.
Continuous intraperitoneal insulin infusion does not increase the risk of organ-specific autoimmune disease in type 1 diabetic patients: results of a multicentric, comparative study.
Dufaitre-Patouraux L, Riveline JP, Renard E, Melki V, Belicar-Schaepelynck P, Selam JL, Guerci B, Millot L, Brun JM, Fermon C, Catargi B, Gin H, Jeandidier N, Lejeune PJ, Lassmann-Vague V. Dufaitre-Patouraux L, et al. Among authors: melki v. Diabetes Metab. 2006 Nov;32(5 Pt 1):427-32. doi: 10.1016/s1262-3636(07)70300-2. Diabetes Metab. 2006. PMID: 17110897 Clinical Trial.
35 results